# A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

> **NCT05055128** · PHASE2 · COMPLETED · sponsor: **Cinclus Pharma AG** · enrollment: 248 (actual)

## Conditions studied

- Erosive Esophagitis

## Interventions

- **DRUG:** X842
- **DRUG:** X842 Dummy
- **DRUG:** Lansoprazole
- **DRUG:** Lansoprazole Dummy

## Key facts

- **NCT ID:** NCT05055128
- **Lead sponsor:** Cinclus Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-11
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-09-01
- **Target enrollment:** 248 (ACTUAL)
- **Last updated:** 2023-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05055128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05055128, "A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT05055128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*